ecrin-mdr-crcClinical2023IPD Sharing (as of September 2023): NoPancreatic cancerMetastatic Malignant NeoplasmProstate cancerEndometrial carcinomaCervical cancerNeoplasmsCervical CancerProstate CancerMetastatic Malignant NeoplasmPancreatic CancerNeoplasmsEndometrial CarcinomaInterventionalhttps://newmdr.ecrin.org/Study/67443United States7Triple negative breast carcinomaRECISTDose escalationRenal cell carcinomaHHLA2OsteosarcomaColorectal carcinomaNon-small cell lung carcinomaGastric gastroesophageal carcinomaUrothelial carcinomaDose expansionCholangiocarcinomaECRIN MDRRecruitingfalseA Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors. The goal of this clinical trial is to learn whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The main questions it aims to answer are: * what is an appropriate dose to be given to patients? * are the side effects of treatment manageable? Participants will be evaluated for participation in the study. Patients who are treated will receive an intravenous infusion of NPX267 every three weeks if their disease has not progressed. Patients will be closely monitored by the treating physician.2023-07-1567443NCT05958199